Technical Analysis for PDSB - PDS Biotechnology Corporation

Grade Last Price % Change Price Change
grade C 3.86 -11.26% -0.49
PDSB closed down 11.26 percent on Thursday, August 6, 2020, on 56 percent of normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Very Strong Up Up Down
Historical PDSB trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.00%
Bearish Engulfing Bearish -11.26%
Inside Day Range Contraction -11.26%
Wide Bands Range Expansion -11.26%
Overbought Stochastic Strength -11.26%
Spinning Top Other -17.34%
Stochastic Reached Overbought Strength -17.34%
Wide Bands Range Expansion -17.34%
Overbought Stochastic Strength -17.34%
180 Bullish Setup Bullish Swing Setup -10.23%

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

PDS Biotechnology Corp, formerly Edge Therapeutics, Inc., is an immuno-oncology company, The Company is focused on developing a pipeline of clinical-stage immunotherapies. Its therapies are developed for the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Versamune is its synthetic lipid-based immunotherapy platform. Its lead product candidate, PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. Its pipeline also includes PDS0102, PDS0103 and PDS0104. Its pipeline of Versamune-based products are all administered by subcutaneous injection .DS0102 is being developed for the treatment of prostate and breast cancers. PDS0103 is based on novel agonist antigens of the mucin-1 (MUC-1) oncogenic C-terminal region. PDS0104 is being developed for the treatment of melanoma.
Medicine Cancer Clinical Medicine Oncology Immunotherapy Cancers Prostate Cancer Breast Cancer Cancer Immunotherapy Immunotherapies Melanoma Head And Neck Cancer Oncolytics Biotech Cervical Cancer Anal Cancer

Is PDSB a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 6.51
52 Week Low 0.61
Average Volume 2,055,351
200-Day Moving Average 1.94
50-Day Moving Average 2.30
20-Day Moving Average 3.45
10-Day Moving Average 3.94
Average True Range 0.54
ADX 70.7
+DI 36.98
-DI 9.82
Chandelier Exit (Long, 3 ATRs ) 3.36
Chandelier Exit (Short, 3 ATRs ) 3.42
Upper Bollinger Band 5.04
Lower Bollinger Band 1.86
Percent B (%b) 0.63
BandWidth 92.24
MACD Line 0.58
MACD Signal Line 0.58
MACD Histogram 0.0064
Fundamentals Value
Market Cap 119.09 Million
Num Shares 30.9 Million
EPS -1.57
Price-to-Earnings (P/E) Ratio -2.46
Price-to-Sales 0.00
Price-to-Book 3.94
PEG Ratio -0.07
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.67
Resistance 3 (R3) 4.76 4.57 4.54
Resistance 2 (R2) 4.57 4.37 4.53 4.49
Resistance 1 (R1) 4.22 4.24 4.13 4.13 4.44
Pivot Point 4.03 4.03 3.99 3.99 4.03
Support 1 (S1) 3.68 3.83 3.59 3.59 3.28
Support 2 (S2) 3.49 3.70 3.45 3.23
Support 3 (S3) 3.14 3.49 3.19
Support 4 (S4) 3.05